Post-results note
Preparing for a wide range of outcomes in 2027 - Q3 review
Elsa Brismar
2026-10-23
08:30 CEST
A weak Q3 reflected missing royalty and delivery timing, while cost savings are now visible. More important, in our view, is the company’s ability to convert its pipeline into orders. The company is preparing for a wide range of 2027 outcomes, balancing tighter cost control with flexibility to ramp up if larger orders materialise. We lower our earnings expectations for 2027, but leave 2028 and long-term estimates unchanged, and maintain our fair value range of SEK18–35 per share.
Weaker-than-expected Q3. Sales were SEK33m, down 61% Y/Y and 42% below our SEK57m estimate. Instead of the sequential step-up we expected, sales fell about 11% Q/Q. Management attributes the weak top line mainly to supply chain delays and deliveries being pushed to Q4 and 2027.
Converting pipeline into firm orders is key. The CEO believes it is too early to conclude that the market is improving but says that interest from Power Generation has taken off, with the Bosch MoU supporting this. Projects in Power Generation can be significantly larger, meaning a single order could materially transform the top line, although timing and conversion remain difficult to assess. PowerCell is preparing for a wide range of 2027 outcomes, with its asset-light model and Bosch partnership allowing capacity to scale while trimming the cost base.
Cost savings are larger and earlier. Combined selling, administrative and R&D costs fell 25% Y/Y, and the annual cost level is expected to be about SEK50m lower in 2027.
Estimate revisions: We adjust our 2026 estimates to include a EUR5m licence fee from Bosch in Q4, lifting profitability by 8%. We make minor top-line revisions and incorporate PowerCell’s updated cost-reduction guidance. This results in a 3%-point reduction to our 2027e EBITDA margin, while leaving our 2028e profitability assumptions unchanged.
Valuation. We keep our fair value range of SEK18–35 per share.